News - Nephrology and Hepatology

Filter

Current filters:

Nephrology and Hepatology

Popular Filters

1 to 25 of 98 results

Amgen announces positive Phase III results for AMG 416 in kidney disease

Amgen announces positive Phase III results for AMG 416 in kidney disease

18-07-2014

USA-based Amgen, the world's leading independent biotech firm, has said its Phase III study evaluating…

AMG 416AmgenChronic kidney diseaseHyperparathyroidismNephrology and HepatologyPharmaceuticalResearchSecondary hyperparathyroidismUSA

Highlights of EMA Pharmacovigilance committee July meeting

Highlights of EMA Pharmacovigilance committee July meeting

14-07-2014

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concluded two safety…

bromocriptineEuropeNephrology and HepatologyNeurologicalPharmaceuticalRegulationRiensoTakeda Pharmaceuticalvalproate Sodium InjectionWomen's Health

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

US nephrologists view hyperphosphatemia treatment

US nephrologists view hyperphosphatemia treatment

11-07-2014

Surveyed nephrologists report awareness of the US Food and Drug Administration's approval of Vifor Fresenius…

AmgenFreseniusGlaxoSmithKlineLa Jolla PharmaceuticalMarkets & MarketingNephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeSensiparUSAvelcalcetideVelphoroVenoferVifor Pharma

Mariel Therapeutics to acquire Stryker's BMP-7 assets

Mariel Therapeutics to acquire Stryker's BMP-7 assets

08-07-2014

US clinical-stage drug developer Mariel Therapeutics has entered into a definitive agreement to acquire…

Anti-Arthritics/RheumaticsMariel TherapeuticsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalStryker Corp

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

Jazz Pharma gains Americas rights to defibrotide from Sigma-Tau

02-07-2014

Ireland-headquartered drugmaker Jazz Pharmaceuticals has signed a definitive agreement Pharmaceuticals…

defibrotideGentiumJazz PharmaceuticalsLicensingNephrology and HepatologyNorth AmericaPharmaceuticalSigma-TauSouth America

Alnylam and TAP collaborate on ALN-AAT, for AAT deficiency-associated liver disease

Alnylam and TAP collaborate on ALN-AAT, for AAT deficiency-associated liver disease

19-06-2014

RNAi therapeutics company Alnylam Pharmaceuticals and The Alpha-1 Project (TAP), the venture philanthropy…

ALN-AATAlnylam PharmaceuticalsBiotechnologyNephrology and HepatologyRegulationResearchThe Alpha-1 ProjectUSA

Retrophin acquires US Thiola rights from Mission Pharmacal

Retrophin acquires US Thiola rights from Mission Pharmacal

30-05-2014

US drugmaker Retrophin has entered into a license agreement with Mission Pharmacal, a private company…

LicensingMission PharmacalNephrology and HepatologyPharmaceuticalRare diseasesRetrophinThiolaUSA

$25 million milestone for Ardelyx from tenapanor deal with AstraZeneca

15-05-2014

Closely-held US biopharma firm Ardelyx has received a $25 million milestone payment from Anglo-Swedish…

ArdelyxAstraZenecaLicensingNephrology and HepatologyPharmaceuticalResearchtenapanor

Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients

14-04-2014

Results from an international Phase III study presented at the European Association for the Study of…

Intercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

Otsuka’s Samsca, first ADPKD therapy, approved in Japan

25-03-2014

Japanese drugmaker Otsuka Pharmaceutical says it has become the first company in the world to obtain…

Asia-PacificJapanNephrology and HepatologyOtsukaPharmaceuticalRegulationSamsca

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex

19-03-2014

German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Strong Ph III data on Intercept’s OCA, but shares hit by side effect concerns

Strong Ph III data on Intercept’s OCA, but shares hit by side effect concerns

17-03-2014

USA-based Intercept Pharmaceuticals reported positive Phase III results on its obeticholic acid (OCA)…

Intercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

13-03-2014

US biotech firm Islet Sciences says it has signed a binding letter of intent to acquire Brighthaven Ventures…

BiotechnologyDiabetesIslet SciencesMergers & AcquisitionsNephrology and Hepatologyremogliflozin

La Jolla’s shares soar as it reports positive results in kidney disease trial

12-03-2014

US-based La Jolla Pharmaceutical Company has announced positive top-line results from its randomized,…

La Jolla PharmaceuticalNephrology and HepatologyPharmaceuticalResearchUSA

Keryx Biopharma files for EU approval of Zerenex

Keryx Biopharma files for EU approval of Zerenex

10-03-2014

US drugmaker Keryx Biopharmaceuticals has submitted a Marketing Authorization Application to the European…

EuropeKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationZerenex

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

25-02-2014

US venture-funded biopharmaceutical company Ardelyx has licensed its novel phosphate transport NaP2b…

ArdelyxAstraZenecaLicensingNaP2bNephrology and HepatologyPharmaceuticalSanofitenapanor

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

29-01-2014

After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application

23-01-2014

US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

Intercept rockets on positive liver disease drug trial

10-01-2014

Shares of USA-based Intercept Pharmaceuticals tripled to $275.87 by close of trading on January 9, when…

Dainippon Sumitomo PharmaIntercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

1 to 25 of 98 results

Back to top